PINX1 Antibody

What is PINX1 and why is it important in cancer research?

PINX1 is a telomerase inhibitor and putative tumor suppressor that plays crucial roles in maintaining chromosome stability. It mediates TRF1 and TERT accumulation in the nucleolus and enhances TRF1 binding to telomeres . PINX1 is particularly important in cancer research because it inhibits telomerase activity, which is activated in most human cancers and critical for cancer cell growth .

PinX1 expression is reduced in most human breast cancer tissues and cell lines, suggesting its role as a tumor suppressor . Furthermore, PinX1 heterozygosity and knockdown activate telomerase and lead to telomerase-dependent chromosomal instability . Recent studies have also revealed that PINX1 maintains cellular DNA damage repair capacity independently of telomerase inhibition, introducing a new facet to its tumor suppressor function .

What epitopes are commonly targeted by PINX1 antibodies?

Commercial PINX1 antibodies typically target different regions of the protein:

• N-terminal region (amino acids 1-150): Often used for detection of full-length PINX1 protein

• Middle region (amino acids 200-300): Suitable for various applications including IP, WB, and IHC-P

• C-terminal region: Used in applications requiring detection of specific PINX1 isoforms

When selecting an antibody, researchers should consider which domain of PINX1 is relevant to their study. For instance, antibodies targeting the N-terminal region (e.g., synthetic peptide DHIKVQVKNNHLGLGATINNEDNWIAHQDD) are commonly used for general PINX1 detection , while those targeting specific functional domains may be more relevant for studying particular aspects of PINX1 biology.

What is the expected molecular weight of PINX1 in Western blot analysis?

The calculated molecular weight of human PINX1 is approximately 37 kDa (37,035 Da specifically) , though the observed molecular weight in Western blot analysis is typically around 40-42 kDa . This slight discrepancy may be due to post-translational modifications. When performing Western blot analysis, researchers should expect to detect PINX1 as a band between 37-42 kDa, depending on the specific cell type and experimental conditions .

How should I optimize Western blot conditions for PINX1 detection?

For optimal Western blot results with PINX1 antibodies:

• Sample preparation: Include protease inhibitors during cell lysis to prevent degradation of PINX1.

• Protein loading: Load 20-50 μg of total protein per lane.

• Antibody dilution: Recommended dilutions vary by antibody source:

  • For Proteintech antibody #12368-1-AP: 1:2000-1:12000

  • For Boster Bio PB9498: Follow manufacturer recommendations for WB applications

• Blocking: 5% non-fat milk in TBST is generally effective.

• Controls: Include positive control samples known to express PINX1 (e.g., HeLa cells, Jurkat cells) .

For enhanced specificity, particularly in cancer research where PINX1 levels may be low, overnight primary antibody incubation at 4°C and high-sensitivity detection reagents are recommended .

What are the recommended fixation and antigen retrieval methods for PINX1 immunohistochemistry?

For successful IHC detection of PINX1:

• Fixation: 10% neutral buffered formalin fixation for 24-48 hours is optimal for tissue preservation.

• Antigen retrieval: Heat-mediated antigen retrieval in citrate buffer (pH 6.0) is effective for most PINX1 antibodies .

• Antibody dilution: For IHC-P applications, dilutions typically range from 1:50-1:500 depending on the antibody .

• Incubation conditions: Overnight incubation at 4°C often yields the best results.

• Detection system: DAB (3,3'-diaminobenzidine) chromogen with hematoxylin counterstaining provides good visualization of nuclear PINX1 .

Research shows that PINX1 is primarily localized in the nucleoli, with additional presence at telomeres , so nuclear/nucleolar staining patterns should be anticipated when evaluating staining specificity.

How can I distinguish between telomerase-dependent and telomerase-independent functions of PINX1 in my experiments?

Distinguishing between these functions requires careful experimental design:

• Complementation assays: Use full-length PINX1 versus PINX1 mutants lacking the telomerase inhibitory domain. Recent research demonstrates that both full-length PINX1 and mutant forms lacking telomerase inhibitory activity can restore vulnerability to etoposide and PARP inhibitors in PINX1-deficient cells .

• Combined knockdown experiments: Perform simultaneous knockdown of PINX1 and telomerase components (TERT or TERC). If a phenotype persists after telomerase knockdown, it suggests a telomerase-independent function.

• Domain-specific analysis: The C-terminal region (amino acids 290-328) of PINX1 is primarily responsible for telomerase inhibition, while other regions mediate additional functions . Using domain-specific antibodies can help elucidate which functions are affected.

• Telomere length assessment: Combine PINX1 manipulation with telomere length analysis (q-FISH or TRF assay) to determine if phenotypes correlate with changes in telomere length .

A recent study revealed that PINX1 maintains cellular DNA damage repair capacity independently of its telomerase inhibition function, as demonstrated by rescue experiments with telomerase-inhibition-deficient PINX1 mutants .

What techniques can be used to study PINX1 interactions with PARP1 and other DNA repair proteins?

Several approaches are effective for studying PINX1 protein interactions:

• Co-immunoprecipitation (Co-IP): Use anti-PINX1 antibodies to pull down protein complexes, followed by Western blot for potential interacting partners. Research has demonstrated PINX1 interaction with PARP1 through this technique .

• Proximity ligation assay (PLA): This technique allows visualization of protein-protein interactions in situ, providing spatial information about where in the cell these interactions occur.

• Chromatin immunoprecipitation (ChIP): ChIP assays using PINX1 antibodies can identify DNA regions where PINX1 and its interacting partners bind, particularly at sites of DNA damage.

• Fluorescence microscopy: Dual immunofluorescence staining with antibodies against PINX1 and PARP1 or other repair factors (e.g., XRCC1) can reveal co-localization at DNA damage sites. Recent research shows that PINX1 facilitates the recruitment of XRCC1 to DNA lesions through binding to the ZnF3-BRCT domain of PARP1 .

• Domain mapping experiments: Use truncated versions of PINX1 to identify which domains are required for interaction with specific partners.

Current research indicates that PINX1 interacts with PARP1 both in the presence and absence of DNA damage, promoting PARP1-chromatin association and transcription of specific DNA damage repair proteins .

How do I control for specificity when studying PINX1 in different cancer types given its variable expression patterns?

Cancer-specific PINX1 expression presents a significant challenge for researchers. To ensure experimental validity:

• Multiple antibody validation: Use at least two different antibodies targeting distinct epitopes of PINX1 to confirm specificity .

• Positive and negative controls: Include known PINX1-expressing cells (e.g., normal breast epithelial MCF-10A) and low-expressing cancer cell lines (several breast cancer cell lines show reduced PINX1) .

• PINX1 knockdown/knockout controls: Generate PINX1 knockdown or knockout cells to verify antibody specificity. Several studies have demonstrated the effectiveness of this approach .

• Cancer-specific expression profiling:

  • Breast cancer: PINX1 expression is reduced in 90% of breast cancer tissues compared to normal tissues

  • Colorectal cancer: PINX1 levels are significantly lower than in normal tissues

  • Prostate cancer: Contradictory findings show both decreased expression in advanced stages and overexpression in some studies

  • Glioma: Expression increases from benign to malignant glioma tissue

• Quantitative approaches: Use qRT-PCR specifically targeting the coding exons to avoid detection of alternatively spliced variants or pseudogenes that can complicate interpretation .

Why might I observe discrepancies between PINX1 mRNA and protein levels in cancer cell lines?

Discrepancies between PINX1 mRNA and protein levels are common and scientifically significant:

For comprehensive analysis, researchers should employ both transcript and protein detection methods, and potentially examine post-translational modifications and chromatin state at the PINX1 locus.

How do I reconcile contradictory findings about PINX1 expression across different cancer studies?

Contradictory findings regarding PINX1 expression in cancer research can be addressed through:

A systematic approach that accounts for these factors can help resolve apparent contradictions in the literature.

How can PINX1 antibodies be utilized to study its role in DNA damage repair beyond telomere maintenance?

Recent research has revealed PINX1's telomerase-independent functions in DNA repair:

• Recruitment studies: Use PINX1 antibodies in ChIP or immunofluorescence to track PINX1 recruitment to DNA damage sites. Recent findings show PINX1 is recruited to DNA lesions through binding to the ZnF3-BRCT domain of PARP1 .

• Protein complex analysis: Employ PINX1 antibodies for co-immunoprecipitation followed by mass spectrometry to identify novel DNA repair factors that interact with PINX1. Research has demonstrated that PINX1 facilitates the downstream recruitment of XRCC1 .

• Chromatin association studies: Use PINX1 antibodies in ChIP-seq experiments to map PINX1 binding sites across the genome in normal and DNA damage conditions.

• Functional domains: Different PINX1 antibodies targeting specific domains can help dissect which regions are required for DNA repair functions versus telomerase inhibition. Recent research has shown that both full-length PINX1 and mutant forms lacking telomerase inhibitory activity can restore vulnerability to genotoxic agents .

• Transcriptional regulation: PINX1 antibodies can be used in ChIP studies to investigate how PINX1 regulates the transcription of DNA repair genes. PINX1 has been shown to promote PARP1-chromatin association and transcription of specific DNA damage repair proteins, including XRCC1 and transcriptional regulators like GLIS3 .

This emerging research area offers significant potential for understanding PINX1's broader role in genome stability.

What experimental approaches can determine whether PINX1's tumor suppressor function is primarily mediated through telomerase inhibition or other mechanisms?

To dissect PINX1's tumor suppressor mechanisms:

• Domain-specific rescue experiments: Introduce wild-type PINX1 or domain-specific mutants into PINX1-deficient cancer cells and assess:

  • Telomerase activity (TRAP assay)

  • Telomere length (q-FISH)

  • Chromosome stability (metaphase spreads)

  • Tumor growth in xenograft models

• Combined genetic approaches: Generate cells with:

  • PINX1 knockout alone

  • Telomerase component knockout alone

  • Double knockout

  Compare phenotypes to determine if PINX1 effects are telomerase-dependent.

• Mechanistic dissection: Recent research has demonstrated that PINX1 maintains DNA damage repair capacity independently of telomerase inhibition , suggesting multiple tumor suppressor mechanisms:

  • Telomerase inhibition: Mediated by C-terminal region

  • DNA repair: Recent data shows interaction with PARP1 and facilitation of XRCC1 recruitment

  • Cell cycle regulation: PINX1 affects cell proliferation through p27/Cyclin E and Cyclin D pathways in glioma

  • Metastasis inhibition: PINX1 inhibits MMP-2 expression and increases TIMP-2 expression

• Cancer-specific analysis: Different cancers may be affected by different PINX1 functions:

  • In colorectal cancer, PINX1 may function as a tumor metastasis inhibitor by negatively regulating the NF-κB/MMP-2 pathway

  • In breast cancer, PINX1 suppresses cell proliferation and triggers apoptosis

These approaches can help determine the relative contribution of each mechanism to PINX1's tumor suppressor function in specific cancer contexts.